Drugs / ExPEC9V
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06134804 | Oct 2023 → Feb 2024 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT04899336 | Jun 2021 → Aug 2025 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-02-13 | Janssen Research & Development, LLC | Results Johnson & Johnson Statement on Phase 3 E.mbrace Study jnj.com ↗
The IDMC conducted a scheduled review of the data available to date, which showed the number of IED cases was similar in both the placebo and active arms of the study, indicating the vaccine regimen did not provide sufficient protection. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-02-13 | Janssen Research & Development, LLC | Johnson & Johnson Statement on Phase 3 E.mbrace Study jnj.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ExPEC9V | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06134804 ↗ |
| Modality | Vaccine | “ExPEC9V (JNJ-78901563, primary compound number: VAC52416) is a 9-valent vaccine candidate in development for active immunization for the prevention of IED in adults 60 years of...” NCT04899336 ↗ |
| Route | Intramuscular | “ExPEC9V will be administered as an IM injection.” NCT04899336 ↗ |